Relmada Therapeutics (RLMD) Misses Q1 EPS by 21c

Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.58), $0.21 worse than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Comcast (CMCSA) Falls Following Comments at Goldman Sachs Conf, Down 4%
• Opus Genetics (IRD) PT Raised to $17 at Citizens
• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent